Proposed Acquisition of Talecris Biotherapeutics

Market Speculation

Melbourne, Australia — 07/05/2009

CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics, Inc. This matter is currently being considered by the U.S. Federal Trade Commission (FTC), including the potential for remedies. This development is not unusual and provides no indication that the deal will, or will not, proceed, or the timing of an FTC decision.

CSL will immediately notify the Australian Stock Exchange as and when it is aware of the decision by the FTC.

Download this release:
  PDF icon Proposed Acquisition of Talecris Biotherapeutics - Market Speculation (0.34 MB)

For further information, please contact:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Telephone: +613 9389 2818
© 2017 CSL Limited